3月28日,再鼎医药(09688/ZLAB)发布截至2024年12月31日止年度的业绩公告。公司总收入为3.99亿美元,同比增长50%;其中,产品收入净额为3.98亿美元,较去年增长49%,主要得益于卫伟迦的上市及其被纳入国家医保目录后销售额的增加,同时则乐和纽再乐的销售也有所增长。公司的净亏损为2.57亿美元,较去年减少23%。2024年公司研发开支总额为2.35亿美元,较上年减少12%,主要是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.